Cheng-Kai Kao to Humans
This is a "connection" page, showing publications Cheng-Kai Kao has written about Humans.
Connection Strength
0.111
-
Implementation of a Real-Time Documentation Assistance Tool: Automated Diagnosis (AutoDx). Appl Clin Inform. 2024 May; 15(3):501-510.
Score: 0.028
-
Use of clinical pathways integrated into the electronic health record to address the coronavirus disease 2019 (COVID-19) pandemic. Infect Control Hosp Epidemiol. 2023 02; 44(2):260-267.
Score: 0.024
-
Consumer Mobile Health Apps: Current State, Barriers, and Future Directions. PM R. 2017 May; 9(5S):S106-S115.
Score: 0.017
-
Neurologic complication after a roller coaster ride. Am J Emerg Med. 2012 Jan; 30(1):249.e5-7.
Score: 0.011
-
Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness. N Engl J Med. 2018 Sep 20; 379(12):1118-1127.
Score: 0.009
-
Extended Thromboprophylaxis with Betrixaban in Acutely Ill Medical Patients. N Engl J Med. 2016 08 11; 375(6):534-44.
Score: 0.008
-
Comparison of Fatal or Irreversible Events With Extended-Duration Betrixaban Versus Standard Dose Enoxaparin in Acutely Ill Medical Patients: An APEX Trial Substudy. J Am Heart Assoc. 2017 Jul 11; 6(7).
Score: 0.004
-
The safety and efficacy of full- versus reduced-dose betrixaban in the Acute Medically Ill VTE (Venous Thromboembolism) Prevention With Extended-Duration Betrixaban (APEX) trial. Am Heart J. 2017 Mar; 185:93-100.
Score: 0.004
-
Extended-Duration Betrixaban Reduces the Risk of Stroke Versus Standard-Dose Enoxaparin Among Hospitalized Medically Ill Patients: An APEX Trial Substudy (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban). Circulation. 2017 02 14; 135(7):648-655.
Score: 0.004
-
The association between transforming growth factor-beta gene promoter C-509T polymorphism and Chinese children with Henoch-Schönlein purpura. Pediatr Nephrol. 2004 Sep; 19(9):972-5.
Score: 0.002